CLINICAL OPPORTUNITIES FOR GERMLINE PHARMACOGENETICS AND MANAGEMENT OF DRUG-DRUG INTERACTIONS IN PATIENTS WITH ADVANCED SOLID CANCERS

4

5 Tyler Shugg, PharmD, PhD^{1*}; Reynold C. Ly, PhD^{1*}; Elizabeth J. Rowe, PhD¹; Santosh Philips,

- 6 PhD^{1} ; Mustafa A. Hyder, MD^{1} ; Milan Radovich, PhD^{2} ; Marc B. Rosenman, MD^{3} ; Victoria M.
- 7 Pratt, PhD⁴; John T. Callaghan, MD, PhD^{1,5}; Zeruesenay Desta, PhD¹; Bryan P. Schneider, MD²;
- 8 Todd C. Skaar, PhD^{1}
- 9
- ¹Division of Clinical Pharmacology, Department of Medicine, Indiana University School of
- 11 Medicine, Indianapolis, IN; ²Division of Hematology/Oncology, Department of Medicine,
- 12 Indiana University School of Medicine, Indianapolis, IN; ³Ann & Robert H. Lurie Children's
- 13 Hospital of Chicago and Institute of Public Health, Feinberg School of Medicine, Northwestern
- 14 University, Chicago, IL; ⁴Department of Medical and Molecular Genetics, Indiana University
- 15 School of Medicine, Indianapolis, IN; ⁵Department of Pharmacology and Toxicology, Indiana
- 16 University School of Medicine, Indianapolis, IN
- 17 *These authors contributed equally to this work
- 18

19 Acknowledgement of Research Support:

- 20 This research was supported by NIGMS R35GM131812 (awarded to TCS) and funds from the
- 21 Indiana University Grand Challenge to support the institutional Precision Health Initiative
- 22 (provides salary and research support to TS, RCL, EJR, SP, MR, BPS, and TCS).
- 23

24 Corresponding Author:

- 25 Todd C. Skaar, PhD
- 26 Professor of Medicine
- 27 Division of Clinical Pharmacology, Department of Medicine
- 28 Indiana University School of Medicine
- 29 Research II, E419
- 30 950 W Walnut St.
- 31 Indianapolis, IN 46202
- 32 Email: tskaar@iu.edu
- 33 Phone: 317-274-2821
- 34
- 35 **<u>Running Head:</u>** Opportunities for precision medicine in advanced cancer patients
- 36
- Where Presented: Presented as a virtual poster at the 2021 annual meeting of the American
 Society for Clinical Pharmacology and Therapeutics
- 39
- 40 41
- 42
- 43
- 44
- 45
- 46

47 ABSTRACT

PURPOSE: Precision medicine approaches, including germline pharmacogenetics (PGx) and 48 management of drug-drug interactions (DDIs), are likely to benefit advanced cancer patients who 49 50 are frequently prescribed multiple concomitant medications to treat cancer and associated conditions. Our objective was to assess the potential opportunities for PGx and DDI management 51 52 within a cohort of adults with advanced cancer. 53 **PATIENTS AND METHODS:** Medication data were collected from the electronic health 54 records (EHRs) for 481 subjects since their first cancer diagnosis. All subjects were genotyped 55 for variants with clinically actionable recommendations in Clinical Pharmacogenetics 56 Implementation Consortium (CPIC) guidelines for 13 pharmacogenes. DDIs were defined as concomitant prescription of strong inhibitors or inducers with sensitive substrates of the same 57 drug-metabolizing enzyme and were assessed for six major cytochrome P450 (CYP) enzymes. 58 59 **RESULTS:** Approximately 60% of subjects were prescribed at least one medication with CPIC recommendations, and ~14% of subjects had an instance for actionable PGx, defined as 60 prescription of a drug in a subject with an actionable genotype. The overall subject-level 61 62 prevalence of DDIs and serious DDIs were 50.3% and 34.8%, respectively. Serious DDIs were most common for CYP3A, CYP2D6, and CYP2C19, occurring in 24.9%, 16.8%, and 11.7% of 63 64 subjects, respectively. When assessing PGx and DDIs together, $\sim 40\%$ of subjects had at least one 65 opportunity for a precision medicine-based intervention and ~98% of subjects had an actionable 66 phenotype for at least one CYP enzyme. 67 **CONCLUSION:** Our findings demonstrate numerous clinical opportunities for germline PGx and DDI management in adults with advanced cancer. 68

69

71 INTRODUCTION

72 Pharmacogenetics (PGx) and management of drug-drug interactions (DDIs) are two aspects of precision medicine that have the potential to optimize medication therapy in oncology 73 and other therapeutic disciplines. PGx-guided approaches have been shown to enhance drug 74 efficacy and safety, including results from prospective clinical trials that have demonstrated the 75 potential for PGx to improve drug safety.¹⁻³ Accordingly, the U.S. Food and Drug 76 77 Administration (FDA) currently includes PGx information within the labels for nearly 300 medications.⁴ Moreover, clinical practice guidelines that include PGx-guided recommendations 78 79 have been published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and 80 prominent discipline-specific professional organizations (e.g., the National Comprehensive Cancer Network) for over 100 medications.^{5,6} Similarly, DDIs are known to contribute to 81 adverse drug events,^{7,8} and strategies to manage DDIs have been shown to improve patient 82 outcomes.⁹ Given their important clinical implications, DDIs constitute a major consideration 83 84 both during drug development and in clinical medicine, and recommendations to manage DDIs are therefore included both in FDA drug development guidance to industry¹⁰ and in numerous 85 clinical practice guidelines.^{11,12} 86

The clinical utility of precision medicine is expected to be especially high for patients 87 88 with advanced cancer given that drug therapy is commonly used not only to treat cancer, but also 89 to manage both cancer treatment-related adverse events (e.g., nausea and vomiting) and comorbid conditions associated with cancer (e.g., psychiatric conditions and pain syndromes). 90 91 As a result, polypharmacy, typically defined as the concomitant use of 5 or more drugs, is exceedingly common in advanced cancer patients.¹³ Polypharmacy carries an increased risk for 92 DDIs,¹⁴ and, predictably, multiple investigations have identified serious DDIs in advanced 93 cancer that impact patient outcomes.¹⁵ PGx-guided approaches also offer the ability to optimize 94

95 therapy for numerous anticancer medications based on somatic and germline genetic biomarkers. 96 While molecular tumor boards have effectively harnessed somatic genome-guided treatment approaches to improve patient outcomes,¹⁶ germline PGx biomarkers can enhance medication 97 safety with agents such as fluoropyrimidine and thiopurine chemotherapies.^{17,18} Additionally, 98 PGx-guided approaches have been shown to enhance both efficacy and safety of selective 99 100 serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and opioid analgesics that are often prescribed for comorbid conditions prevalent in cancer.¹⁹⁻²¹ Given these abundant 101 102 PGx opportunities in cancer patients, it has been suggested that preemptive testing for PGx variants at first cancer diagnosis may be an effective clinical strategy to optimize patient 103 outcomes.²² Furthermore, recent advancements in bioinformatics technology have enhanced the 104 feasibility of PGx approaches in cancer through the creation of methods to extract PGx 105 106 information from existing germline sequencing data generated during the clinical workflow of molecular tumor boards.^{23,24} 107

Although past studies have characterized opportunities for DDI management and PGx-108 109 guided approaches in patients with advanced cancer, we are not aware of any work that has simultaneously investigated both approaches to provide a comprehensive assessment of the 110 potential for precision medicine. Therefore, the objective of this study was to determine 111 112 composite opportunities for precision medicine, incorporating both PGx-guided and DDI management strategies, within a cohort of adults with advanced solid cancers. By analyzing the 113 potential for PGx-guided interventions since each subject's respective date of first cancer 114 diagnosis, we also directly investigate the potential clinical utility of preemptively obtaining PGx 115 116 information when patients are first diagnosed with cancer.

117

118 METHODS

119 Subject Enrollment and Eligibility

120 This study was a retrospective electronic health record (EHR) review and prospective genotyping of eligible patients with solid cancers at Indiana University Health in Indianapolis, 121 122 Indiana, USA. Subjects were eligible to participate in the study if they 1) had been seen in the Indiana University Health Precision Genomics clinic and enrolled in the accompanying Indiana 123 University Total Cancer Care Protocol (part of the larger Oncology Research Information 124 Exchange Network-wide Total Cancer Care initiative [https://www.oriencancer.org/]) and 2) 125 agreed to submit a blood sample for genotyping. Subjects were enrolled into the study at clinic 126 visits from February 2015 to February 2018. This research protocol, as well as the parent Total 127 Cancer Care Protocol, were approved by Indiana University's Institutional Review Board. All 128 subjects provided written informed consent. 129

130

131 Study Design and Data Collection

The purpose of this study was to investigate potential opportunities for precision 132 133 medicine interventions, including PGx and management of DDIs, within a cohort of 481 adults seen at our institutional precision oncology clinic and associated solid tumor board. 134 Demographic and clinical data, including medication prescriptions, were collected from the 135 EHRs of all institutions participating in the Indiana Health Information Exchange, a statewide 136 EHR data repository that includes 38 healthcare systems. Demographic data included age, sex, 137 and race. Clinical data included first oncologic diagnosis and all inpatient and outpatient 138 139 prescriptions. Genotyping for major pharmacogenes was performed at the College of American 140 Pathologists-accredited Indiana University Pharmacogenomics Laboratory using a laboratorydeveloped assay based on the OpenArray[®] Platform (ThermoFisher; Waltham, MA). The genes 141

142	included on the genotyping platform, along with the number of variants tested for each gene,
143	were as follows: CYP2B6 (2), CYP2C19 (6), CYP2C9 (6), CYP2D6 (11, including copy number
144	targeting exon 9), CYP3A4 (2), CYP3A5 (3), CYP4F2 (1), DPYD (2), G6PD (2), IFNL3 (1),
145	SLCO1B1 (2), TPMT (2), and VKORC1 (1). Detailed genotyping methods are provided in the
146	Supplemental Methods, and a complete list of tested variants is shown in Table S1.
147	
148	Medication Inclusion into Precision Medicine Analyses
149	The PGx analysis included 46 medications with published guidelines as of 09/25/20 by
150	CPIC (full list available in Table S2 and online). ⁵ Drugs were considered for inclusion in the
151	DDI analysis if they were listed as substrates, inhibitors, or inducers of CYP2B6, CYP2C19,
152	CYP2C8, CYP2C9, CYP2D6, or CYP3A within 1) the "Clinical substrates," "Clinical
153	inhibitors," or "Clinical inducers" tables of the current version (as of 09/25/20) of the U.S. Food
154	and Drug Administration's "Drug Development and Drug Interactions: Table of Substrates,
155	Inhibitors and Inducers" ²⁵ or 2) the Indiana University School of Medicine's Drug Interactions
156	Flockhart Table TM . ²⁶ Medications contained in these resources were reviewed for inclusion into
157	DDI analyses based on the expertise of the study team. The final list of included substrates,
158	inhibitors, and inducers are displayed in Table S2. Medications included in the DDI analysis
159	between tyrosine kinase inhibitors (TKIs) and acid reducers are also listed in Table S2. Within
160	our analyses, acid reducers included antacids, histamine-2 receptor antagonists (H2RAs), proton
161	pump inhibitors (PPIs), and sucralfate.
162	

163 PGx Analyses

164	Within our analyses, PGx recommendations for drug-gene pairs were classified by
165	genotype-predicted phenotype (e.g., metabolizer status) based on annotations from the
166	Pharmacogenomics Knowledge Base (PharmGKB). Phenotypes were considered actionable if
167	CPIC guidelines recommended a clinical action to manage the drug-gene interaction (see File S1
168	for actionability determinations). Specific clinical actions included adjustment of initial or
169	maintenance dosing, selection of alternative therapy, or performing additional tests to determine
170	enzyme activity.

Using these determinations, we considered genotype-predicted phenotypes as actionable within our phenotype distribution (**Table 2**) if CPIC guidelines for one or more drug-gene pairs recommended clinical action based on the specified phenotype. For our analyses characterizing the prevalence of actionable PGx opportunities, we only included instances where a medication was prescribed to a subject with a CPIC-defined actionable genotype-predicted phenotype for that same medication (e.g., prescription of clopidogrel in a CYP2C19 poor metabolizer).

177

178 DDI Analyses

DDIs involving CYP enzymes were defined as concomitant prescription of an inhibitor or inducer with a sensitive substrate of the same drug-metabolizing enzyme. To account for temporal delays in CYP induction and de-induction following the onset and offset of CYP inducers, the window for DDIs with co-administered CYP substrates was defined as starting 7 days after initiation of inducer therapy and lasting 7 days after termination of inducer therapy. DDIs involving CYP enzymes were analyzed for CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, and CYP3A for each patient from their date of first cancer diagnosis until the last date

186	of data collection (04/20/20). DDIs were also assessed for concomitant prescription of drug-drug
187	pairs that included TKIs and medications known to reduce gastrointestinal acidity.
188	Extracted medication data contained the date, time, and location (i.e., whether
189	administered in a medical setting, including outpatient clinics, or whether dispensed from a
190	pharmacy) for each prescription. The days supply for each prescription was conservatively
191	estimated using the following assumptions. For prescriptions administered in a medical setting,
192	the days supply was assumed to be one. For prescriptions dispensed from a pharmacy, the days
193	supply was assumed based on the shortest days supply for indications for which the drug is
194	typically prescribed (see Table S3 for a complete list of assumed durations for all prescriptions
195	dispensed from a pharmacy). An exception to this method was made for prescriptions dispensed
196	from a pharmacy that were 1) dispensed for at least three consecutive regular intervals (e.g.,
197	every 30 days, every 90 days) and 2) written for medications that are commonly used as
198	maintenance therapy for chronic medical conditions (e.g., antihypertensives). For these
199	prescriptions, the patient was assumed to be taking the medication for the entire interval between
200	consecutive prescriptions.
201	Instances of autoinhibition and autoinduction (i.e., a medication altering its own
202	metabolism upon chronic administration) were not considered as DDIs in our analyses. In
203	addition, DDIs involving common chemotherapy regimens (e.g., prednisone and docetaxel) were

205 were also not considered as DDIs.

204

We defined "serious DDIs" as DDI pairs with sensitive substrate drugs that have one or more of the following: 1) a narrow therapeutic index, 2) indications as cancer treatments, or 3) an association with significant adverse drug reactions (see bolded drugs in **Table S2**).

not included in our analyses. Instances of co-administration of multiple proton pump inhibitors

2	0	9
_	v	-

210	Composite Precision Medicine Analyses
211	The prevalence of CYP inhibitor-mediated phenoconversion was assessed for CYP2B6,
212	CYP2C19, CYP2C9, CYP2D6, and CYP3A4. Within our analyses, we coded subjects as
213	positive for CYP inhibitor-mediated phenoconversion if they were (1) genotype-predicted
214	ultrarapid, rapid, normal, or intermediate metabolizers and (2) prescribed a relevant strong CYP
215	inhibitor at any time after first cancer diagnosis.
216	
217	Statistical Analyses
218	Data for the PGx and DDI analyses were analyzed using descriptive statistics (counts and
219	percentages) using JMP Pro v.15.0.0.
220	
221	RESULTS
222	Subject Demographic, Clinical, and Medication Data
223	Demographic and clinical characteristics of the 481 study subjects with advanced cancer
224	included are shown in Table 1. Our cohort was a median of 57 ± 16.6 (median \pm interquartile
225	range [IQR]) years old, and most subjects were white (87.9%) and female (53.2%). The most
226	common types of cancer at first diagnosis included breast (12.7%), pancreatic (10.8%), and
227	colorectal (9.6%). The median duration of follow-up, defined as the time between the date of
228	first cancer diagnosis and the date of last prescription, was 2.9 ± 4.9 (median \pm IQR) years.
229	Extracted medication data contained ≥ 1 prescription for 469 out of 481 (97.5%) subjects.
230	Filtering to include only prescriptions since each subject's respective date of first cancer
231	diagnosis yielded 158,188 unique prescriptions that were assessed within our precision medicine

232	analyses (schematic of filtering results shown in Figure S1). Since first cancer diagnosis, our
233	cohort had 1) a total of 7,074 unique prescriptions for medications contained within a CPIC
234	guideline (herein called "PGx medications") and 2) a total of 22,642 unique prescriptions for
235	medications that were defined as inducers, inhibitors, or sensitive substrates of CYP2B6,
236	CYP2C19, CYP2C8, CYP2C9, CYP2D6, and/or CYP3A, acid reducers, or TKIs (herein called
237	"DDI medications").
238	
239	PGx Analyses
240	The distribution of genotype-predicted phenotypes within our cohort for all
241	pharmacogenes is displayed in Table 2. When defining actionable phenotypes as those with
242	clinically actionable recommendations within CPIC guidelines for at least one medication, the
243	rates of actionable phenotypes were highest for CYP2C19 (59.5%) and VKORC1 (52.4%) and
244	lowest for TPMT (7.3%), G6PD (1.5%), and DPYD (1.0%).
245	Of 469 analyzed subjects, 282 (60.1%) were prescribed at least one PGx medication.
246	These included a total of 1,045 unique PGx medications (i.e., prescription of a unique PGx
247	medication for a unique subject), with an average of 2.2 ± 2.4 (mean \pm standard deviation) PGx
248	medications/subject and a maximum of 12 PGx medications in one subject. When considering
249	both prescribed medications and genotype-predicted phenotypes, we identified a total of 81
250	unique opportunities for "actionable PGx," defined as an instance where a PGx medication was
251	prescribed to a subject with an actionable phenotype based on CPIC recommendations. Instances
252	of actionable PGx occurred for 67 subjects (14.3%), with 56 subjects having instances of
253	actionable PGx involving 1 medication, 8 subjects having actionable PGx involving 2
254	medications, and 3 subjects having actionable PGx involving 3 medications.

255	The prevalence of instances of actionable PGx, when stratified by the drug-gene pairs
256	involved, are shown in Table 3. For PGx medications prescribed in at least five subjects, the
257	rates of actionable PGx were highest for warfarin (87.5%), amitriptyline (58.3%), and
258	clopidogrel (42.9%). Conversely, capecitabine, 5-fluorouracil, sertraline, and celecoxib had no
259	instances for actionable PGx. For warfarin, subjects had actionable PGx recommendations based
260	on CYP2C9, CYP4F2, and VKORC1 genotype-based phenotypes in 20.8%, 58.3%, and 50.0% of
261	cases, respectively. For amitriptyline, subjects had actionable PGx recommendations based on
262	CYP2C19 and CYP2D6 genotype-based phenotypes in 16.7% and 50.0% of cases, respectively.
263	
264	DDI Analyses
265	Of 469 analyzed subjects, the prevalence of ≥ 1 prescription for an inducer, inhibitor, or
266	substrate of any CYP enzyme was 49.0%, 58.0%, and 64.0%, respectively. Figure S2 displays
267	the prevalence of subjects with prescriptions for inducers, inhibitors, and substrates across the six
268	enzyme systems that were assessed. Prescriptions for CYP inducers were most common for
269	CYP2C19, CYP2C9, and CYP3A, occurring in 49.0% of subjects. Prescriptions for inhibitors
270	were most common for CYP2D6 (occurring in 53.3% of subjects), CYP2C9 (35.0%), CYP3A
271	(33.9%), and CYP2C19 (31.8%), while prescriptions for sensitive substrates were most common
272	for CYP3A, CYP2D6, and CYP2C19 (prescribed in 60.3%, 59.9%, and 48.2% of subjects,
273	respectively).
274	When assessing concomitant prescription of both a relevant perpetrator (inducer or
275	inhibitor) and victim (sensitive substrate) drug, 236 subjects (50.3%) had a DDI affecting at least
276	one CYP enzyme system. Given the frequent use of corticosteroids to treat and manage
277	treatment-related complications for many types of cancer, ²⁷ we also performed DDI analyses

278	excluding corticosteroids, which are potent inducers of CYP2C19, CYP2C9, and CYP3A; 225
279	subjects (48.0%) had a DDI affecting at least one major CYP enzyme when excluding
280	corticosteroids. As shown in Table 4, the prevalence of DDIs in our cohort was highest for
281	CYP2D6 (affecting 45.2% of subjects; average of 1.5 DDIs/subject), followed by CYP3A
282	(29.9%; 0.8 DDIs/subject), CYP2C19 (23.9%; 0.5 DDIs/subject), CYP2C9 (11.7%; 0.2
283	DDIs/subject), CYP2B6 (0.2%), and CYP2C8 (0%). When excluding corticosteroids, the
284	prevalence of DDIs for CYP2C19, CYP2C9, and CYP3A was reduced to 10.2%, 7.0%, and
285	20.3%, respectively (Table 4). The most common drug-drug pairs contained within observed
286	DDIs, stratified by enzyme, are shown in Table S4. The subject-level prevalence for serious
287	DDIs, which were classified by the substrates involved, was 34.8% for any CYP enzyme when
288	including corticosteroids and 29.4% when excluding corticosteroids (Table 4). Serious DDIs
289	were most common for CYP3A, occurring in 24.9% of subjects and including sensitive
290	substrates like fentanyl, midazolam, and tramadol. In contrast, serious DDIs were less common
291	for CYP2C19 (11.7% of subjects; sensitive substrates included escitalopram, sertraline, and
292	citalopram), CYP2C9 (4.7% of subject; substrates included warfarin, dronabinol, and phenytoin),
293	and CYP2D6 (16.8% of subject; substrates included tramadol, sertraline, and mirtazapine).
294	When adjusting the prevalence of CYP enzyme-mediated DDIs based on subject genotype (i.e.,
295	excluding DDIs involving inducer or inhibitor drugs in subjects who are genotype-predicted poor
296	metabolizers), the subject-level prevalence is as follows: CYP2B6: 0.2%; CYP2C19: 23.9%;
297	CYP2C8: 0%; CYP2C9: 11.7%; CYP2D6: 44.1%; and CYP3A: 29.6% (adjusted based on
298	CYP3A4 genotype).
299	TKIs have emerged as first-line treatment options for a variety of cancers. However,

300 multiple investigations have described the potential for significant DDIs involving orally-

301	administered TKIs and acid reducing agents, including antacids, H2RAs, and PPIs, that reduce
302	TKI bioavailability and impact treatment outcomes. ²⁸⁻³¹ Accordingly, we characterized the
303	prevalence of DDIs involving TKIs and acid reducers in our study population. Within our cohort,
304	68 subjects (14.5%) were prescribed at least one TKI, with pazopanib (prescribed in 17 subjects),
305	sunitinib (10), and crizotinib (9) being the most commonly prescribed. Of the 68 subjects
306	prescribed a TKI, 33 (48.5%) had a concomitant prescription of at least one acid reducer. Within
307	our population, the most common acid reducer classes involved in DDIs were PPIs (perpetrator
308	drug in 34 DDIs), followed by H2RAs (10) and antacids (6).
309	
310	Composite Precision Medicine Analyses
311	To assess the prevalence of composite opportunities for precision medicine interventions,
312	we aggregated findings from our actionable PGx, serious CYP-mediated DDI, and acid reducer-
313	TKI DDI analyses at the subject level. As shown in Figure 1, 186 subjects (39.7%) had at least
314	one opportunity for a precision medicine intervention. 68 subjects (14.5%) had opportunities for
315	more than one type of precision medicine intervention, with 9 of these subjects (1.9%) having
316	opportunities for PGx and management of both CYP-mediated and acid reducer-TKI DDIs.
317	Finally, we assessed the prevalence of CYP inhibitor-mediated phenoconversion, the
318	process by which co-administration of a strong inhibitor functionally converts those with any
319	genotype to a poor metabolizer phenotype, for CYP2B6, CYP2C19, CYP2C9, CYP2D6, and
320	CYP3A4. As shown in Figure 2, CYP inhibitor-mediated phenoconversion enhanced the
321	number of subjects with actionable phenotypes for CYP2C19, CYP2C9, and CYP2D6, and
322	CYP3A4, increasing the prevalence from 59.5% to 72.8%, 33.3% to 55.9%, 44.7% to 76.3%,
323	and 8.9% to 38.9%, respectively. In contrast, CYP inhibitor-mediated phenoconversion only

324	slightly changed the number of actionable phenotypes for CYP2B6 (prevalence increased from
325	48.4% to 49.1%) due to the low prevalence of prescription of CYP2B6 inhibitors within our
326	cohort. When considering all five investigated CYPs together, nearly every subject in our cohort
327	(98.3%) had an actionable phenotype (either genotype-predicted or from CYP inhibitor-mediated
328	phenoconversion) for at least one CYP since their date of first cancer diagnosis. Also, 47
329	subjects (9.8%) had genotype-predicted or phenoconverted actionable phenotypes for all five
330	CYP enzymes.

331

332 **DISCUSSION**

In this investigation, we provide quantitative evidence to support the immense clinical 333 opportunities for precision medicine approaches, including germline PGx and management of 334 335 DDIs, in a cohort of patients with advanced cancer. Our findings indicate that ~14% of subjects 336 had opportunities for actionable PGx (i.e., prescription of a PGx medication to a subject with a CPIC guideline-defined actionable genotype) and that ~35% and ~7% of subjects had a serious 337 338 DDI involving major CYP enzymes and acid reducers co-prescribed with TKIs, respectively. When incorporating both PGx and DDIs, we found that ~40% of subjects had at least one 339 opportunity for a precision medicine-based intervention and nearly all subjects (~98%) had an 340 341 actionable phenotype (genetically-predicted or drug-induced) for ≥ 1 CYP enzyme. Based on our findings, implementation of precision medicine approaches at first cancer diagnosis is likely to 342 provide clinical benefit to a significant proportion of patients. Although a limited number of 343 other studies have addressed similar topics, our investigation has significant methodological 344 345 advantages, including 1) a larger cohort (n=481), 2) a broader PGx analysis consisting of 13

CPIC-actionable pharmacogenes, and 3) utilization of a statewide data repository to enable morecomprehensive collection of medication data.

Previous investigations have demonstrated the potential clinical impact of PGx 348 349 approaches in patients with advanced cancer. Nichols, et al. catalogued medications in a cohort of 193 patients with advanced cancer, demonstrating that 65% of patients were taking at least 350 one PGx medication (i.e., those with a CPIC guideline).³² Using population estimates of allele 351 352 frequencies, the authors predicted that 7.1% of patients in their cohort could benefit from at least 353 one PGx intervention involving medications associated with nine major pharmacogenes: CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-B, SLCO1B1, VKORC1. 354 Similarly, Hertz, et al. found that 2.6% of 115 adult and pediatric patients with cancer could have 355 benefitted from a PGx intervention involving substrates of their analyzed drug-metabolizing 356 enzymes, which included CYP2C19, DPYD, and TPMT.³³ An investigation by Kasi, et al. also 357 predicted abundant opportunities for PGx interventions within their cohort of 155 patients with 358 advanced cancer based on patient genotypes for major CYP450 enzymes, though they did not 359 specifically collect and analyze medication data.³⁴ Many of our findings are similar to those 360 reported in past investigations. For instance, our findings related to the prevalence of prescription 361 of PGx medications are remarkably similar to results from Nichols, et al. when considering both 362 prescription of any PGx medication (~60% in our analysis vs. 65% in their study) and 363 prescription of specific PGx drugs such as ondansetron, capecitabine, and simvastatin.³² Our 364 findings related to the distribution of actionable phenotypes are also consistent with those from 365 past investigations^{32,34} as well as those predicted from large analyses of population allele 366 frequencies.³⁵ In contrast, our finding for the prevalence of subjects with potential PGx 367 368 interventions (14.3%) is higher than those reported by Nichols, et al. (7.1%) or Hertz, et al.

(2.6%).^{32,33} These differences are likely attributable to the facts that we (1) investigated the 369 370 potential for PGx interventions across a wider array of pharmacogenes and (2) that we utilized a 371 statewide repository with prescription data from 38 health systems to enhance the richness of our 372 collected medication data. Multiple investigations have also characterized the clinical potential of DDI management 373 strategies in adult patients with advanced cancer. A 2009 review by Riechelmann, et al. 374 375 summarized the prevalence of potential DDIs from six studies, finding rates between 27% and 72%.³⁶ The high variability they observed among studies is likely attributable to differences in 376 employed methodologies (e.g., utilizing patient-verified medication lists versus all drugs listed in 377 EHRs, focusing on all potential drug interactions versus only those involving cancer 378 medications). More recently, investigations within the U.S. and abroad have characterized the 379 prevalence of potential DDIs in cancer patients, finding rates of 40-78%.³⁷⁻⁴¹ Again, it appears 380 that observed differences in potential DDI prevalence are due to methodological differences 381 382 among the studies. For instance, we found that studies that included DDIs based on both 383 pharmacokinetic (i.e., concomitant administration of an inhibitor or inducer of a drugmetabolizing enzyme along with a sensitive substrate of that enzyme) and pharmacodynamic 384 (i.e., concomitant administration of two or more drugs with the same adverse event profile) 385 mechanisms had higher rates of potential DDIs.^{38,39} Similarly, studies that utilized medication 386 lists taken from the EHR (rather than those verified by patients during medication reconciliation) 387 had higher potential DDI prevalence.^{38,39} The overall DDI prevalence of ~52% in our study falls 388 in the middle of those reported by past investigations. In terms of methodology, extracting 389 medication data from the EHR likely resulted in a higher DDI prevalence in our study relative to 390 391 those that used patient-verified medications. We attempted to control for this by utilizing

392 prescription dates to only identify potential DDIs when there was temporal overlap in the 393 prescription (and presumed coadministration) of perpetrator and victim drugs for the same CYP enzyme. Relative to other studies, our DDI prevalence was likely more conservative based on 394 395 other elements in our methodology, including (1) that we excluded DDIs with pharmacodynamic mechanisms and (2) that we excluded DDIs involving drugs commonly co-administered as 396 397 cancer treatment regimens (e.g., corticosteroids co-administered with docetaxel or vincristine). 398 Our rationale for excluding these DDIs was that, in the case of pharmacodynamic DDIs, coadministration of drugs with similar adverse event profiles is often clinically indicated (e.g., dual 399 400 antiplatelet therapy) and, in the case of DDIs within established cancer regimens, treating 401 clinicians are familiar with these DDIs and have likely already determined a favorable riskbenefit ratio for the patient before prescribing. Therefore, based on these methodological 402 403 elements, we believe our findings represent a conservative estimate of the prevalence of potential DDIs in advanced cancer patients involving major CYP enzymes. Additionally, our study 404 expands on past investigations assessing potential DDI prevalence in a few significant ways. 405 406 First, our results stratified DDI prevalence by the CYP enzymes involved, which could aid clinicians in selecting drugs with metabolic pathways less likely to be associated with DDIs. 407 Next, we specifically investigated the prevalence of DDIs for acid reducing agents and TKIs, 408 which has emerged as an important consideration in cancer precision medicine.⁴² Finally, we 409 410 performed both a composite subject-level analysis and CYP inhibitor-mediated phenoconversion analysis to elucidate the net prevalence of precision medicine opportunities in our study cohort 411 412 that incorporate both PGx and DDI management approaches.

Our findings are impactful since they demonstrate the abundant clinical opportunities for
precision medicine approaches to optimize medication therapy in patients with advanced cancer.

415 Specifically, we found that $\sim 60\%$ of subjects in our cohort were prescribed at least one PGx 416 medication and that approximately 1 in 7 subjects had an opportunity for actionable PGx since 417 their date of first cancer diagnosis. These findings directly support the clinical utility of PGx 418 approaches in patients with cancer, including the suggestion of preemptive genotyping at first cancer diagnosis.²² Advances in technology have also improved the feasibility of PGx 419 approaches by reducing the costs associated with obtaining genetic information and enabling 420 repurposing of genetic information obtained from molecular tumor boards.²⁴ In addition, 421 422 economic analyses have demonstrated cost savings due to toxicity sparing for both DPYD and *TPMT* testing.^{43,44} As a result, there is clinical momentum for standardized testing of PGx 423 markers associated with fluoropyrimidine and thiopurine chemotherapies.^{45,46} Our findings also 424 corroborate those from other studies^{32,34} in identifying significant opportunities for PGx to 425 426 optimize supportive care therapies in patients with cancer, including SSRIs, TCAs, opioids, and commonly used antiemetics (e.g., ondansetron), based on CPIC guidelines.^{19-21,47} 427 Related to the clinical opportunities for DDI management strategies, we found that 428 429 slightly over half of our study subjects had a DDI affecting at least one major CYP enzyme since first cancer diagnosis. This finding is important given that DDIs have been associated with poor 430 clinical outcomes and increased adverse drug events in cancer patients. For instance, CYP-431 mediated DDIs have been shown to increase the rates of adverse events attributable to both 432 cancer therapies (e.g., increased paclitaxel-induced peripheral neuropathy during co-treatment 433 with clopidogrel)⁴⁸ and concomitant medications (e.g., increased warfarin-induced bleeding 434 during co-treatment with capecitabine)⁴⁹ in patients with cancer. Additionally, several studies 435 436 have investigated the potential for DDIs between acid reducing agents and TKIs, demonstrating 437 reduced progression-free and overall survival during concomitant therapy attributed to reduced

TKI systemic absorption.²⁸⁻³⁰ Our findings support the potential for clinically significant DDIs 438 439 between acid reducers and TKIs since we observed that these DDIs occurred in nearly half of 440 subjects that were prescribed a TKI. However, it is possible that the providers told the patient to 441 discontinue the acid reducers while taking the TKI's. Nonetheless, our findings support the clinical potential of DDI management strategies, which have been shown to improve outcomes in 442 other populations,⁹ in patients with advanced cancer. Finally, our work serves as one of the first 443 investigations to assess the prevalence of potential drug-drug-gene interactions (DDGIs) (i.e., 444 445 CYP inhibitor-mediated phenoconversion) within a clinical cohort. While the strategies to 446 manage DDGIs borrow from both PGx and DDI management approaches, consideration of DDGIs may provide critical information that modifies the risk of adverse drug events predicted 447 from consideration of either approach in isolation.⁵⁰ As demonstrated by our composite study 448 449 findings that $\sim 40\%$ of subjects had at least one opportunity for precision medicine intervention 450 and ~98% of subjects had an actionable phenotype for \geq 1 CYP enzymes, PGx information and 451 concomitant drug lists should be used in tandem to most accurately inform approaches to 452 optimize medication therapy. Given the complexities of DDGIs, including concepts like phenoconversion and interplay of multiple drug biotransformation pathways, expert guidance 453 that includes perspectives from both clinical pharmacologists and clinicians is needed to inform 454 455 actionable clinical management strategies.

We acknowledge several limitations of our study. First, our extracted medication data did not include a way to conclusively ascertain days supply in order to assess temporal overlap between perpetrator and victim drugs within our DDI analyses. To compensate for this limitation, we used conservative methods in our DDI analyses to estimate days supply for each prescription, as described in the methods. While this limitation may have influenced our findings

461 related to the prevalence of DDIs, it did not impact results from our PGx analyses. Our extracted 462 medication data also did not consistently contain information about the medication dose. As a result, our analysis may have overestimated the prevalence of instances for actionable PGx with 463 464 amitriptyline since current CPIC guidelines do not recommend clinical action at daily doses under 50 mg.¹⁹ Also, our panel-based genotyping method only tested for relatively common 465 functional variants in the assessed genes within our primary ethnic and racial populations, 466 potentially excluding rare functional variants that alter drug response. While we do not expect 467 that this approach significantly impacted our findings, it is important to note that utilizing panel-468 469 based genotyping (as opposed to a more complete approach like whole genome sequencing) may have caused us to underestimate the actual clinical opportunities for actionable PGx in our 470 cohort. Additionally, advances in knowledge since study initiation limited our ability to assess 471 472 variants with newly established relevance to pharmacotherapy (e.g., HapB3 in DPYD).Our 473 genotyping panel also did not assess every pharmacogene included within a CPIC guideline. 474 However, the pharmacogenes covered in our panel serve as the genetic basis for over 80% of the PGx recommendations contained within current CPIC guidelines.⁵ 475

In conclusion, our work provides quantitative evidence of the vast clinical opportunities 476 for precision medicine approaches in patients with advanced cancer, demonstrating the clinical 477 478 utility of both germline PGx and DDI management strategies. Given their established clinical benefits and the abundant opportunities for their use demonstrated by our results, precision 479 480 medicine approaches are likely to improve medication outcomes in cancer patients and may 481 provide clinical benefit if incorporated into the workflow of molecular tumor boards. In order to facilitate widespread adoption of precision medicine approaches in this high-value patient 482 483 population, future research is needed to (1) prospectively demonstrate the clinical benefit of

- 484 precision medicine approaches on patient outcomes and to (2) identify effective strategies for
- 485 clinical implementation of precision medicine approaches.

- 487 ACKNOWLEDGEMENTS
- 488 None

489 **REFERENCES**

- Claassens DMF, Vos GJA, Bergmeijer TO, et al: A Genotype-Guided Strategy for Oral
 P2Y(12) Inhibitors in Primary PCI. N Engl J Med 381:1621-1631, 2019
- 492 2. Mallal S, Phillips E, Carosi G, et al: HLA-B*5701 screening for hypersensitivity to abacavir.
 493 N Engl J Med 358:568-79, 2008
- 494 3. Pirmohamed M, Burnside G, Eriksson N, et al: A randomized trial of genotype-guided
 495 dosing of warfarin. N Engl J Med 369:2294-303, 2013
- 4. U.S. Food and Drug Administration: Table of Pharmacogenomic Biomarkers in Drug
 Labeling, (ed 08/18/20), 2020
- 498 5. Clinical Pharmacogenetics Implementation Consortium: Guidelines, 2020
- 6. Shugg T, Pasternak AL, London B, et al: Prevalence and types of inconsistencies in clinical
 pharmacogenetic recommendations among major U.S. sources. NPJ Genom Med 5:48, 2020
- 501 7. Bates DW, Cullen DJ, Laird N, et al: Incidence of adverse drug events and potential adverse
 502 drug events. Implications for prevention. ADE Prevention Study Group. Jama 274:29-34,
 503 1995
- Wright A, Feblowitz J, Phansalkar S, et al: Preventability of adverse drug events involving multiple drugs using publicly available clinical decision support tools. Am J Health Syst Pharm 69:221-7, 2012
- Arnold RJG, Tang J, Schrecker J, et al: Impact of Definitive Drug-Drug Interaction Testing
 on Medication Management and Patient Care. Drugs Real World Outcomes 5:217-224, 2018
- 10. U.S. Food and Drug Administration: Clinical Drug Interaction Studies -- Cytochrome P450
 Enzyme- and Transporter-Mediated Drug Interactions: Guidance for Industry, (ed January
 2020), 2020
- 512 11. Department of Health and Human Services Office of AIDS Research Advisory Council:
 513 Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2018
- 12. Grundy SM, Stone NJ, Bailey AL, et al: 2018
- 515 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline
- on the Management of Blood Cholesterol: A Report of the American College of
- 517 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
 518 Circulation 139:e1082-e1143, 2019
- LeBlanc TW, McNeil MJ, Kamal AH, et al: Polypharmacy in patients with advanced cancer
 and the role of medication discontinuation. Lancet Oncol 16:e333-41, 2015
- 14. Guthrie B, Makubate B, Hernandez-Santiago V, et al: The rising tide of polypharmacy and
 drug-drug interactions: population database analysis 1995-2010. BMC Med 13:74, 2015
- 523 15. Sharma M, Vadhariya A, Chikermane S, et al: Clinical Outcomes Associated with Drug-
- Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based
 Literature Review. Drugs Aging 36:341-354, 2019
- 16. Kato S, Kim KH, Lim HJ, et al: Real-world data from a molecular tumor board demonstrates
 improved outcomes with a precision N-of-One strategy. Nat Commun 11:4965, 2020
- 17. Relling MV, Schwab M, Whirl-Carrillo M, et al: Clinical Pharmacogenetics Implementation
 Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes:
- 530
 2018 Update. Clin Pharmacol Ther 105:1095-1105, 2019
- 18. Amstutz U, Henricks LM, Offer SM, et al: Clinical Pharmacogenetics Implementation
 Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and
- 533 Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 103:210-216, 2018

- Hicks JK, Sangkuhl K, Swen JJ, et al: Clinical pharmacogenetics implementation consortium
 guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic
 antidepressants: 2016 update. Clin Pharmacol Ther 102:37-44, 2017
- 20. Crews KR, Gaedigk A, Dunnenberger HM, et al: Clinical Pharmacogenetics Implementation
 Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014
- update. Clin Pharmacol Ther 95:376-82, 2014
- 540 21. Hicks JK, Bishop JR, Sangkuhl K, et al: Clinical Pharmacogenetics Implementation
- Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of
 Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 98:127-34, 2015
- 543 22. Hoffman JM, Haidar CE, Wilkinson MR, et al: PG4KDS: a model for the clinical
 544 implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet
 545 166c:45-55, 2014
- 546 23. van der Lee M, Allard WG, Bollen S, et al: Repurposing of Diagnostic Whole Exome
 547 Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics. Clin Pharmacol Ther
 548 107:617-627, 2020
- 24. Numanagić I, Malikić S, Ford M, et al: Allelic decomposition and exact genotyping of highly
 polymorphic and structurally variant genes. Nat Commun 9:828, 2018
- 25. U.S. Food and Drug Administration: Drug Development and Drug Interactions: Table of
 Substrates, Inhibitors and Inducers, (ed 03/10/20), 2020
- 26. Indiana University School of Medicine: Drug Interactions Flockhart Table, 2020
- 27. Lossignol D: A little help from steroids in oncology. J Transl Int Med 4:52-54, 2016
- 28. Chen YM, Lai CH, Chang HC, et al: Antacid Use and De Novo Brain Metastases in Patients
 with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were
 Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine
 Kinase Inhibitors. PLoS One 11:e0149722, 2016
- 29. Chu MP, Ghosh S, Chambers CR, et al: Gastric Acid suppression is associated with
 decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 16:33-9, 2015
- 30. Ha VH, Ngo M, Chu MP, et al: Does gastric acid suppression affect sunitinib efficacy in
 patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 21:194-200,
 2015
- 31. Mir O, Touati N, Lia M, et al: Impact of Concomitant Administration of Gastric Acid Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated
 within the EORTC 62043/62072 Trials. Clin Cancer Res 25:1479-1485, 2019
- 32. Nichols D, Arnold S, Weiss HL, et al: Pharmacogenomic potential in advanced cancer
 patients. Am J Health Syst Pharm 76:415-423, 2019
- 33. Hertz DL, Glatz A, Pasternak AL, et al: Integration of Germline Pharmacogenetics Into a
 Tumor Sequencing Program. JCO Precis Oncol 2, 2018
- 34. Kasi PM, Koep T, Schnettler E, et al: Feasibility of Integrating Panel-Based
 Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With
 Colorectal Cancer, Technol Cancer Res Treat 18:1533033819873924, 2019
- 35. Zhou Y, Ingelman-Sundberg M, Lauschke VM: Worldwide Distribution of Cytochrome
 P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol
 Ther 102:688-700, 2017
- 36. Riechelmann RP, Del Giglio A: Drug interactions in oncology: how common are they? Ann
 Oncol 20:1907-12, 2009

579	37. Chen L, Cheung WY: Potential drug interactions in patients with a history of cancer. Curr
580	Oncol 21:e212-20, 2014
581	38. Ismail M, Khan S, Khan F, et al: Prevalence and significance of potential drug-drug
582	interactions among cancer patients receiving chemotherapy. BMC Cancer 20:335, 2020
583	39. Korucu FC, Senyigit E, Köstek O, et al: A retrospective study on potential drug interactions:
584	A single center experience. Journal of Oncological Sciences 4:80-84, 2018
585	40. van Leeuwen RW, Brundel DH, Neef C, et al: Prevalence of potential drug-drug interactions
586	in cancer patients treated with oral anticancer drugs. Br J Cancer 108:1071-8, 2013
587	41. van Leeuwen RW, Swart EL, Boven E, et al: Potential drug interactions in cancer therapy: a
588	prevalence study using an advanced screening method. Ann Oncol 22:2334-41, 2011
589	42. Yu G, Zheng QS, Wang DX, et al: Drug interactions between tyrosine-kinase inhibitors and
589 590	acid suppressive agents: more than meets the eye. Lancet Oncol 15:e469-70, 2014
	43. Zarca K, Durand-Zaleski I, Loriot MA, et al: Modeling the Outcome of Systematic TPMT
591 502	
592	Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis. Mol Diagn Ther 23:429-438, 2019
593	44. Fragoulakis V, Roncato R, Fratte CD, et al: Estimating the Effectiveness of DPYD
594 505	Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of
595 506	Chemotherapy-Induced Toxicity. Am J Hum Genet 104:1158-1168, 2019
596 507	45. Weitzel KW, Smith DM, Elsey AR, et al: Implementation of Standardized Clinical Processes
597 508	
598 500	for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clin Transl Sci 11:175-181, 2018
599	,
600	46. Hertz DL, Sahai V: Including DPYD on Cancer Genetic Panels to Prevent Fatal
601 602	Fluoropyrimidine Toxicity. J Natl Compr Canc Netw 18:372-374, 2020
602 602	47. Bell GC, Caudle KE, Whirl-Carrillo M, et al: Clinical Pharmacogenetics Implementation
603	Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
604 605	Clin Pharmacol Ther 102:213-218, 2017
605 606	48. Agergaard K, Mau-Sørensen M, Stage TB, et al: Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. Clin Pharmacol Ther 102:547-553, 2017
607 608	49. Shah HR, Ledbetter L, Diasio R, et al: A retrospective study of coagulation abnormalities in
608	patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 5:354-8, 2006
609 610	50. Malki MA, Pearson ER: Drug-drug-gene interactions and adverse drug reactions.
	Pharmacogenomics J 20:355-366, 2020
611	Filamacogenomics J 20.555-500, 2020
612	
613	
010	
614	
615	
616	
617	
64.6	
618	

FIGURE LEGENDS

- Figure 1. Subject-level prevalence for composite precision medicine opportunities, including
- actionable PGx, management of serious CYP-mediated DDIs, and management of DDIs
- 622 including acid reducers and TKIs.

- Figure 2. Subject-level prevalence of clinically actionable phenotypes for major CYP enzymes
- based on genotype and due to CYP inhibitor-mediated phenoconversion.

642 TABLES

Table 1. Demographic and clinical characteristics of study cohort with advanced cancer.

Variable	Value in Full
	Cohort (n=481)
Age in years at first cancer diagnosis (median [IQR])	57.4 (16.6)
Sex_(Count [Percent])	
Female	256 (53.2%)
Male	225 (46.8%)
Race (Count [Percent])	
White	423 (87.9%)
Black	38 (7.9%)
Asian	8 (1.7%)
Other*	3 (0.4%)
Unknown	9 (1.9%)
Cancer type at first diagnosis	
(Count [Percent])	
Breast	61 (12.7%)
Pancreatic	52 (10.8%)
Colorectal	46 (9.6%)
Prostate	40 (8.3%)
Soft-tissue sarcoma	36 (7.5%)
Ovarian	26 (5.4%)
Non-small cell lung	23 (4.8%)
Renal	18 (3.7%)
Thymic	13 (2.7%)
Cholangiocarcinoma	12 (2.5%)
Head and neck	11 (2.3%)
Bladder	10 (2.1%)
Unknown primary	13 (2.7%)
Duration of follow-up in years ⁺ (median [IQR])	2.9 (4.9)

*One individual who reported a race of "other" reported Hispanic ethnicity.

⁺Defined as the time elapsed between the date of first cancer diagnosis and date of most recent

646 prescription

Table 2. Distribu	able 2. Distribution of genotype-predicted phenotypes within study cohort for major pharmacogenes.						
	Ultrarapid	Normal	Intermediate	Poor			
Gene	Metabolizer	Metabolizer	Metabolizer	Metabolizer	Indeterminate	Actionable	
CYP2B6		248 (51.6%)	199 (41.4%)	34 (7.1%)		233 (48.4%)	
<i>YP2C19</i>	153 (31.8%)*	189 (39.3%)	124 (25.8%)	9 (1.9%)	6 (1.2%)	286 (59.5%)	
YP2C9		321 (66.7%)	146 (30.4%)	14 (2.9%)		160 (33.3%)	
YP2D6	9 (1.9%)	254 (52.8%)	182 (37.8%)	24 (5.0%)	12 (2.5%)	215 (44.7%)	
YP3A4		437 (90.9%)	41 (8.5%)	2 (0.4%)	1 (0.2%)	$43~(8.9\%)^{\pm}$	
YP3A5		17 (3.5%)	71 (14.8%)	391 (81.3%)	2 (0.4%)	88 (18.3%)	
YP4F2		265 (55.1%)	175 (36.4%)	41 (8.5%)		216 (44.9%)	
PYD		476 (99.0%)	5 (1.0%)	0 (0%)		5 (1.0%)	
5PD ⁺		474 (98.5%)	4 (0.8%)	3 (0.6%)		7 (1.5%)	
NL3 (IL28B) ⁺		204 (42.4%)	220 (45.7%)	57 (11.9%)		0 (0%)	
<i>CO1B1</i> ⁺		333 (69.2%)	107 (22.2%)	11 (2.3%)	30 (6.2%)	118 (24.5%)	
PMT		440 (91.5%)	35 (7.3%)	0 (0%)	6 (1.2%)	35 (7.3%)	
KORC1 ⁺		229 (47.6%)	199 (41.4%)	53 (11.0%)		252 (52.4%)	
*For CYP2C19, count in ultrarapid metabolizer column includes counts of both ultrarapid metabolizers (n=20) and rapid metabolizer							
=133).							
⁺ For designated genes, "normal metabolizer," "intermediate metabolizer," and "poor metabolizer" designations refer to subj							
are non-carriers, heterozygous, and homozygous for CPIC-defined actionable variants, respectively. [±] While CPIC does not make <i>CYP3A4</i> genetic-guided recommendations for any drugs, we classify subjects with one or two cop							
Vhile CPIC does	not make CYP3.	A4 genetic-guide	ed recommendati	ons for any drug	gs, we classify sub	pjects with one o	

Table 2. Distribution of genotype-p	redicted phenotypes within stud	y cohort for major pharmacogenes.
rusie zi zistristation of genotype p	realected phenoty pes within stad	g conorerer major priarmacogenesi

are non-carriers, heterozygous, and [±]While CPIC does not make CYP3 the CYP3A4*22 loss-of-function allele as intermediate and poor metabolizers, respectively, and consider these phenotypes to be actionable since they are used at our institution to guide tacrolimus dosing in CYP3A5 non-expressers.

# Prescribed Drug	% with Actionable PGx						
256	0.8%						
171	4.7%						
99	2.0%						
93	5.4%						
81	6.2%						
62	0%						
40	0%						
28	0%						
25	12.0%						
24	4.2%						
24	87.5%						
21	23.8%						
21	23.8%						
16	12.5%						
15	0%						
12	58.3%						
9	11.1%						
8	12.5%						
7	42.9%						
7	14.3%						
6	16.7%						
6	33.3%						
3	100%						
3	66.7%						
2	0%						
1	0%						
1	0%						
1	100%						
1	0%						
1	0%						
1	0%						
Total 1045							
	$\begin{array}{c c} 256 \\ \hline 171 \\ 99 \\ 93 \\ \hline 81 \\ 62 \\ 40 \\ 28 \\ 25 \\ 24 \\ 24 \\ 24 \\ 21 \\ 21 \\ 16 \\ 15 \\ 12 \\ 9 \\ 8 \\ 7 \\ 7 \\ 6 \\ 6 \\ 6 \\ 3 \\ 3 \\ 2 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$						

Table 3. Prevalence of PGx medications prescribed in subjects with clinically actionable genotype-predicted phenotypes based on CPIC recommendations.

The "number prescribed drug" indicates the number of subjects within our cohort that were prescribed the corresponding drug. The "percent with actionable PGx," which was calculated at the subject-level, indicates the percent of subjects prescribed the corresponding drug that had genotypes for which current CPIC guidelines recommend actionable clinical management strategies.

Table 4. Number and prevalence of unique DDIs (i.e., unique co-prescription of a relevant drug-drug pair in a unique subject) by enzyme involved in n=469 subjects prescribed \geq 1 medication, including (left) and excluding (right) DDIs involving corticosteroids.

	DDIs Including Corticosteroids				DDIs Excluding Corticosteroids			
	Total	DDIs/Subject	DDI	Serious DDI	Total	DDIs/Subject	DDI	Serious DDI
Enzyme	DDIs	(Mean)	Prevalence (%)	Prevalence (%)	DDIs	(Mean)	Prevalence (%)	Prevalence (%)
CYP2B6	1	0.00	0.2%	0.2%	1	0.00	0.2%	0.2%
CYP2C19	237	0.51	23.9%	11.7%	89	0.19	10.2%	5.8%
CYP2C8	0	0	0%	0%	0	0	0%	0%
CYP2C9	76	0.16	11.7%	4.7%	39	0.08	7.0%	2.3%
CYP2D6	695	1.48	45.2%	16.8%	695	1.48	45.2%	16.8%
CYP3A	392	0.84	29.9%	24.9%	217	0.46	20.3%	18.6%
Any DDI	1401	2.99	50.3%	34.8%	1041	2.22	48.0%	29.4%

Note: All DDI prevalence calculations are at the subject level.

FIGURES

Figure 1.



